Sunday, 1 Jun 2025
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • DMCA
Subscribe
Brinks Report
  • Featured
  • Money Matters
  • Business
  • IPL
  • Technology
  • Automobile
  • Entertainment
  • Sports
  • More
    • People
    • World
    • Health and Wellness
    • Horoscope
  • Today’s News
  • 🔥
  • World
  • Business
  • Economy
  • Technology
  • Automobile
  • IPL
  • People
  • Sports
  • IPL 2025
  • Entertainment
Font ResizerAa
Brinks ReportBrinks Report
Search
  • Featured
  • Money Matters
  • Business
  • IPL
  • Technology
  • Automobile
  • Entertainment
  • Sports
  • More
    • People
    • World
    • Health and Wellness
    • Horoscope
  • Today’s News
Have an existing account? Sign In
Follow US
© 2024-2025 Brinks Report. All content, including text, images, and other media, is copyrighted.
Brinks Report > Blog > Business > Alembic Pharmaceuticals Receives One US FDA Observation for Vadodara Facility, Plans to Respond Soon
BusinessEconomy

Alembic Pharmaceuticals Receives One US FDA Observation for Vadodara Facility, Plans to Respond Soon

Ankita Das
Last updated: March 8, 2025 1:50 pm
Ankita Das
Share
Copy of www. Brinksreport. Com 29
SHARE
Trulli

Alembic Pharmaceuticals, a well-known pharmaceutical company, announced that its bioequivalence facility in Vadodara, Gujarat, was recently inspected by the United States Food and Drug Administration (US FDA). The inspection took place from March 3 to March 7, 2025.

After the inspection, the US FDA issued a Form 483 with one procedural observation regarding the company’s operations at this facility. A Form 483 is a notice from the US FDA that highlights any issues found during an inspection that may not meet regulatory standards.

Trulli

In a statement released after market hours on Friday, Alembic Pharmaceuticals confirmed that the issue was procedural and assured that it would submit a detailed response to the US FDA within the required time frame. The company did not provide specific details about the observation but mentioned that it would take necessary corrective actions, which is a normal part of the regulatory process.

Despite this news, Alembic Pharmaceuticals’ stock rose by 4.26% on the Bombay Stock Exchange (BSE), closing at Rs 845.65.

Financial Performance

Alembic Pharmaceuticals has faced some financial challenges recently. In Q3 FY25 (October-December 2024), the company’s consolidated net profit dropped by 23.29% to Rs 138.42 crore, compared to Rs 180.45 crore in the same period last year (Q3 FY24). However, the company’s revenue from operations increased by 3.81% year-on-year (YoY) to Rs 1,692.74 crore, showing growth in its core business.

Read More: Shilpa Medicare’s Raichur Unit Receives US FDA Form 483: What It Means for the Pharma Giant

What’s Next for Alembic?

Alembic’s response to the US FDA’s observation and its efforts to maintain regulatory compliance will be crucial for its global business. The company remains focused on following international standards, which is important for investor confidence and future growth.

Although the US FDA’s observation is a concern, the stock market’s positive reaction suggests that investors believe Alembic will handle the situation well. Stakeholders will be closely watching how the company resolves this issue and its performance in the coming months.

Image Slider
Image 1 Image 2 Image 3
TAGGED:AlembicPharmaForm483PharmaceuticalNewsUSFDAVadodara
Share This Article
Facebook Whatsapp Whatsapp Copy Link Print
What do you think?
Love0
Sad0
Happy0
Joy0
Sleepy0
Angry0
Surprise0
Previous Article Why mrbeast says his $85 million life is a gilded cage Why MrBeast Says His $85 Million Life Is a Gilded Cage
Next Article New epa policy New EPA Policy: Purchases over $50,000 need approval from Elon Musk’s DOGE
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Your Trusted Source for Accurate and Timely Updates!

Brink’s Report delivers fresh, unbiased, and engaging content across politics, business, tech, entertainment, and more. From breaking news to deep dives, we keep you informed—and intrigued—with accurate reporting and diverse perspectives. Explore the world, one story at a time.
FacebookLike
XFollow
RSS FeedFollow
Ad image

You Might Also Like

Cil tender for 200 mw solar panel factory in uttar pradesh
Business

India’s Solar Revolution Begins! CIL Announces Tender for 200 MW Solar Factory in Uttar Pradesh – Are You Ready for the Green Future?

By
Ankita Das
India demands $1. 4b from volkswagen - will this scare off foreign investors?
Business

India Demands $1.4B From Volkswagen – Will This Scare Off Foreign Investors?

By
Dolon Mondal
Godrej industries q4 profit soars 2. 44% to rs 183 crore
Economy

Godrej Industries Shares Rise 2.44% to Rs 1,152.40 as Q4 FY25 Profit Jumps to Rs 183.08 Crore

By
Ankita Das
Nifty psu bank
Business

Nifty PSU Bank Surges 3%, Investor Wealth Jumps Rs 3.7 Lakh Crore

By
Dolon Mondal
Ad image

About US


Brink’s Report delivers fresh, unbiased, and engaging content across politics, business, tech, entertainment, and more. From breaking news to deep dives, we keep you informed—and intrigued—with accurate reporting and diverse perspectives. Explore the world, one story at a time.

Top Categories
  • World
  • Business
  • Economy
  • Technology
Usefull Links
  • Contact Us
  • About Us
  • Privacy Policy
  • DMCA

© 2024-2025 Brinks Report. All content, including text, images, and other media, is copyrighted.